216 related articles for article (PubMed ID: 12874512)
1. Positron emission tomography of soft tissue sarcomas.
Israel-Mardirosian N; Adler LP
Curr Opin Oncol; 2003 Jul; 15(4):327-30. PubMed ID: 12874512
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
[TBL] [Abstract][Full Text] [Related]
3. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
4. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
[No Abstract] [Full Text] [Related]
5. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
6. Functional image in soft tissue sarcomas: An update of the indications of
Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas.
Lucas JD; O'Doherty MJ; Wong JC; Bingham JB; McKee PH; Fletcher CD; Smith MA
J Bone Joint Surg Br; 1998 May; 80(3):441-7. PubMed ID: 9619933
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of
Kassem TW; Abdelaziz O; Emad-Eldin S
Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778
[TBL] [Abstract][Full Text] [Related]
9. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
[TBL] [Abstract][Full Text] [Related]
10. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. PET for sarcomas other than gastrointestinal stromal tumors.
Toner GC; Hicks RJ
Oncologist; 2008; 13 Suppl 2():22-6. PubMed ID: 18434635
[TBL] [Abstract][Full Text] [Related]
13. Fluorodeoxyglucose positron emission tomography scanning: basic principles and imaging of adult soft-tissue sarcomas.
Conrad EU; Morgan HD; Vernon C; Schuetze SM; Eary JF
J Bone Joint Surg Am; 2004; 86-A Suppl 2():98-104. PubMed ID: 15691114
[No Abstract] [Full Text] [Related]
14. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
15. PET-CT in the Evaluation of Neoadjuvant/Adjuvant Treatment Response of Soft-tissue Sarcomas: A Comprehensive Review of the Literature.
Castillo-Flores S; Gonzalez MR; Bryce-Alberti M; de Souza F; Subhawong TK; Kuker R; Pretell-Mazzini J
JBJS Rev; 2022 Dec; 10(12):. PubMed ID: 36639875
[TBL] [Abstract][Full Text] [Related]
16. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
Peterson JJ
Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
[TBL] [Abstract][Full Text] [Related]
17. Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial.
Erfanian Y; Grueneisen J; Kirchner J; Wetter A; Podleska LE; Bauer S; Poeppel T; Forsting M; Herrmann K; Umutlu L
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1823-1831. PubMed ID: 28567495
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography imaging in uterine sarcomas: systematic review and meta-analysis of the literature.
Sadeghi R; Zakavi SR; Hasanzadeh M; Treglia G; Giovanella L; Kadkhodayan S
Int J Gynecol Cancer; 2013 Oct; 23(8):1349-56. PubMed ID: 23945203
[TBL] [Abstract][Full Text] [Related]
19. PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin.
Katal S; Gholamrezanezhad A; Kessler M; Olyaei M; Jadvar H
PET Clin; 2018 Oct; 13(4):609-621. PubMed ID: 30219191
[TBL] [Abstract][Full Text] [Related]
20. The Role of Imaging in Soft Tissue Sarcoma Diagnosis and Management.
Sharon CE; Straker RJ; Karakousis GC
Surg Clin North Am; 2022 Aug; 102(4):539-550. PubMed ID: 35952686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
